Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Suda shows far more promise than its ‘penny-dreadful’ status suggests

September 29, 2019September 30, 2019 | Tim Boreham

Health & Biotech

The Health Kick Podcast with Tim Boreham: Oventus Medical

September 25, 2019January 24, 2020 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: PharmAust wants a piece of the +$US10.2b pet drug market

September 22, 2019September 22, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Imagion gears up for human breast cancer trials, but market value falls way short of peers

September 16, 2019September 15, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Antisense wants to conquer the less crowded DMD market

September 9, 2019September 8, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: What Anatara needs for its diarrhoea treatment to be more than just snake oil

September 2, 2019September 1, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: How SomnoMed is placed in the $10.4 billion sleep apnoea market

August 26, 2019August 25, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Opthea needs some big licks of dough, but it has set itself up for success

August 19, 2019August 19, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: It’s glory or bust as Shareroot ramps up its social standing

August 11, 2019August 11, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Regeneus has pain sorted; now for long-term gain

August 5, 2019August 4, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Has Imugene now got the assets it needs to fast-track an acquisition?

July 29, 2019July 28, 2019 | Tim Boreham

Health & Biotech

Dr Boreham’s Crucible: Pharmaxis shareholders breathe easy – the FDA loves you

July 22, 2019July 22, 2019 | Tim Boreham